Research Article
BibTex RIS Cite

Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications

Year 2020, Volume: 3 Issue: 3, 194 - 204, 31.12.2020

Abstract

Analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) have gastrointestinal side effects and,
particularly for local pain, topical dosage forms of these drugs are mainly preferred. The aim of this study
was to develop meloxicam loaded niosomal hydrogel for enhanced transdermal and controlled drug
delivery. Niosomal formulations were prepared by thin film hydration method using different types of nonionic surfactant in the presence of cholesterol. Niosomal vesicles were characterized in terms of droplet
size, zeta potential, surface morphology and entrapment efficiency. For enhanced residence time, niosomes
were further loaded into the carbopol gel. The niosomal formulation containing Span 60, Tween 80 and
cholesterol at a molar ratio of 6:1:0.6 had an optimally high percentage of drug entrapment with a mean
vesicular diameter of 236.80 nm. Within 24 hours, a maximum of 46.83% drug release was achieved
showing faster releasing profile than commercial meloxicam gel. Dermal and transdermal delivery of
meloxicam using niosomal-gel formulations may offer promising alternative to traditional delivery systems
of non-steroidal anti-inflammatory drugs with improved local and systemic but decreased adverse effects.

References

  • Ah YC, Choi JK, Choi YK, Ki HM, Bae JH (2010). A novel transdermal patch incorporating meloxicam: In vitro and in vivo characterization. Int J Pharm 385(1–2): 12–19.
  • El-nabarawi MA, Bendas ER, El-ridy MS, Abdel GA, Nasr-alla SM (2015). Research Article Formulation and evaluation of topical niosomal gel of baclofen. J Chem Pharm 7(1): 277–288.
  • Engelhardt G, Homma D, Schlegel K, Utzlnann R, Schnitzler C (1995). Anti-inflammatory , analgesic , antipyretic and related properties of meloxicam , a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 433: 423–433.
  • FDA. (2017). Statistical Approaches to Evaluate Analytical Similarity - Guidance for Industry. French DL, Himmelstein KJ, Mauger JW (1995). Physicochemical aspects of controlled release of substituted benzoic and naphthoic acids from Carbopol ® gels. J Control Release 37: 281–289.
  • Graeme KA (2005). Nonsteroidal Anti-inflammatory Drugs. Critical Care Toxicology 1219-1236.
  • Gupta M, Vaidya B, Mishra N, Vyas SP (2011). Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery. Artif Cells Nanomed Biotechnol 39(6): 376–384.
  • Hao Y, Zhao F, Li N, Yang Y, Li K (2002). Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm 244(1–2): 73–80.
  • Kassaye L, Genete G (2013). Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules. Afr Health Sci 13(2): 369–375.
  • Lengert EV, Talnikova E, Tuchin VV (2020). Prospective Nanotechnology-Based Strategies for Enhanced Intra- and Transdermal Delivery of Antifungal Drugs. Skin Pharmacol Physiol 410012: 261–269.
  • Manconi M, Sinico C, Valenti D, Loy G, Fadda AM (2002). Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm 234(1–2): 237–248.
  • Noble S, Balfour JA (1996). Meloxicam. Drugs 51(3): 424–430.
  • Nowroozi F, Almasi A, Javidi J, Haeri A, Dadashzadeh S (2018). Effect of surfactant type, cholesterol content and various downsizing methods on the particle size of niosomes. Iran J Pharm Sci 17(Special Issue 2): 1–11.
  • Patel KK, Kumar P, Thakkar HP (2012). Formulation of Niosomal Gel for Enhanced Transdermal Lopinavir Delivery and Its Comparative Evaluation with Ethosomal Gel. AAPS PharmSciTech 13(4): 1502–1510.
  • Peppas NA, Bures P, Leobandung W, Ichikawa H (2000). Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 50(1): 27–46.
  • Qumbar M, Sarim S, Ali J, Ahmad J, Ali A (2017). ScienceDirect Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery : In-vitro characterization and in-vivo activity. Biomed 93: 255–266.
  • Santos Júnior A de F, Barbosa IS, dos Santos VL, Silva RL, Caetite Junior E (2014). Test of dissolution and comparison of in vitro dissolution profiles of coated ranitidine tablets marketed in Bahia, Brazil. Braz J Pharm Sci 50(1): 83–89.
  • Simionato LD, Petrone L, Baldut M, Bonafede SL, Segall AI (2018). Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. SPJ 26(4): 578–584. Sternberg B, Florence AT (1994). Preparation and properties of vesicles (niosomes) and a sorbitan triester (Span 85). Int J Pharm 105: 1–6.
  • Tavano L, Gentile L, Oliviero Rossi C, Muzzalupo R (2013). Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery. Colloids Surf B 110: 281–288.
Year 2020, Volume: 3 Issue: 3, 194 - 204, 31.12.2020

Abstract

References

  • Ah YC, Choi JK, Choi YK, Ki HM, Bae JH (2010). A novel transdermal patch incorporating meloxicam: In vitro and in vivo characterization. Int J Pharm 385(1–2): 12–19.
  • El-nabarawi MA, Bendas ER, El-ridy MS, Abdel GA, Nasr-alla SM (2015). Research Article Formulation and evaluation of topical niosomal gel of baclofen. J Chem Pharm 7(1): 277–288.
  • Engelhardt G, Homma D, Schlegel K, Utzlnann R, Schnitzler C (1995). Anti-inflammatory , analgesic , antipyretic and related properties of meloxicam , a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 433: 423–433.
  • FDA. (2017). Statistical Approaches to Evaluate Analytical Similarity - Guidance for Industry. French DL, Himmelstein KJ, Mauger JW (1995). Physicochemical aspects of controlled release of substituted benzoic and naphthoic acids from Carbopol ® gels. J Control Release 37: 281–289.
  • Graeme KA (2005). Nonsteroidal Anti-inflammatory Drugs. Critical Care Toxicology 1219-1236.
  • Gupta M, Vaidya B, Mishra N, Vyas SP (2011). Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery. Artif Cells Nanomed Biotechnol 39(6): 376–384.
  • Hao Y, Zhao F, Li N, Yang Y, Li K (2002). Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm 244(1–2): 73–80.
  • Kassaye L, Genete G (2013). Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules. Afr Health Sci 13(2): 369–375.
  • Lengert EV, Talnikova E, Tuchin VV (2020). Prospective Nanotechnology-Based Strategies for Enhanced Intra- and Transdermal Delivery of Antifungal Drugs. Skin Pharmacol Physiol 410012: 261–269.
  • Manconi M, Sinico C, Valenti D, Loy G, Fadda AM (2002). Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm 234(1–2): 237–248.
  • Noble S, Balfour JA (1996). Meloxicam. Drugs 51(3): 424–430.
  • Nowroozi F, Almasi A, Javidi J, Haeri A, Dadashzadeh S (2018). Effect of surfactant type, cholesterol content and various downsizing methods on the particle size of niosomes. Iran J Pharm Sci 17(Special Issue 2): 1–11.
  • Patel KK, Kumar P, Thakkar HP (2012). Formulation of Niosomal Gel for Enhanced Transdermal Lopinavir Delivery and Its Comparative Evaluation with Ethosomal Gel. AAPS PharmSciTech 13(4): 1502–1510.
  • Peppas NA, Bures P, Leobandung W, Ichikawa H (2000). Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 50(1): 27–46.
  • Qumbar M, Sarim S, Ali J, Ahmad J, Ali A (2017). ScienceDirect Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery : In-vitro characterization and in-vivo activity. Biomed 93: 255–266.
  • Santos Júnior A de F, Barbosa IS, dos Santos VL, Silva RL, Caetite Junior E (2014). Test of dissolution and comparison of in vitro dissolution profiles of coated ranitidine tablets marketed in Bahia, Brazil. Braz J Pharm Sci 50(1): 83–89.
  • Simionato LD, Petrone L, Baldut M, Bonafede SL, Segall AI (2018). Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. SPJ 26(4): 578–584. Sternberg B, Florence AT (1994). Preparation and properties of vesicles (niosomes) and a sorbitan triester (Span 85). Int J Pharm 105: 1–6.
  • Tavano L, Gentile L, Oliviero Rossi C, Muzzalupo R (2013). Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery. Colloids Surf B 110: 281–288.
There are 18 citations in total.

Details

Primary Language English
Subjects Pharmacology and Pharmaceutical Sciences
Journal Section Research Article
Authors

Leyla Beba Pojarani

Sheida Zarifiazar

Publication Date December 31, 2020
Published in Issue Year 2020 Volume: 3 Issue: 3

Cite

APA Beba Pojarani, L., & Zarifiazar, S. (2020). Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications. EMU Journal of Pharmaceutical Sciences, 3(3), 194-204.
AMA Beba Pojarani L, Zarifiazar S. Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications. EMUJPharmSci. December 2020;3(3):194-204.
Chicago Beba Pojarani, Leyla, and Sheida Zarifiazar. “Formulation and Chracterization of Meloxicam Loaded Niosome-Based Hydrogel Formulations for Topical Applications”. EMU Journal of Pharmaceutical Sciences 3, no. 3 (December 2020): 194-204.
EndNote Beba Pojarani L, Zarifiazar S (December 1, 2020) Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications. EMU Journal of Pharmaceutical Sciences 3 3 194–204.
IEEE L. Beba Pojarani and S. Zarifiazar, “Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications”, EMUJPharmSci, vol. 3, no. 3, pp. 194–204, 2020.
ISNAD Beba Pojarani, Leyla - Zarifiazar, Sheida. “Formulation and Chracterization of Meloxicam Loaded Niosome-Based Hydrogel Formulations for Topical Applications”. EMU Journal of Pharmaceutical Sciences 3/3 (December 2020), 194-204.
JAMA Beba Pojarani L, Zarifiazar S. Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications. EMUJPharmSci. 2020;3:194–204.
MLA Beba Pojarani, Leyla and Sheida Zarifiazar. “Formulation and Chracterization of Meloxicam Loaded Niosome-Based Hydrogel Formulations for Topical Applications”. EMU Journal of Pharmaceutical Sciences, vol. 3, no. 3, 2020, pp. 194-0.
Vancouver Beba Pojarani L, Zarifiazar S. Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications. EMUJPharmSci. 2020;3(3):194-20.